Texas Retina Associates’ Robert C. Wang, MD, co-authored an article titled “Management of Repository Corticotropin Injection Therapy for Non‐infectious Uveitis: A Delphi Study” in the March 2021 issue of the medical journal Acta Ophthalmologica.
What is Non-infectious Uveitis?
Uveitis is a rare retinal disease where the body’s immune system attacks the eye, causing inflammation. Non-infectious uveitis can result from an eye injury or a disease somewhere else in the body. It is a major cause of blindness worldwide, and diagnosis and management of the condition can be challenging. The primary treatment, corticosteroids, is not appropriate for long-term use.
Repository Corticotropin Injection Treatment
Repository corticotropin injection (RCI) is a purified, sterile preparation of the natural form of adrenocorticotropic hormone (ACTH) in gelatin to provide a prolonged release after injection. It is believed to affect uveitis by multiple mechanisms and has received regulatory approval for treatment of ophthalmic diseases, including posterior uveitis. However, it is not widely used or discussed in guidelines for the management of uveitis and ocular inflammatory diseases.
This study surveyed a panel of 14 US‐based ophthalmologists who reached consensus that RCI may be an appropriate treatment option for some patients with uveitis when other therapies are ineffective or intolerable.
You can access the full abstract here.
About Dr. Wang
Dr. Wang provides a full range of retina care and sub-specializes in the diagnosis and treatment of uveitis. He sees patients in our Dallas Main, Dallas North, Plano and Sherman offices. Dr. Wang also serves as Director of Clinical Research for our Plano office. You can learn more about him here.